In addition to Dr. Henney, Mike Hooven,
chairman and CTO of AtriCure, a Cincinnati-based company focused on the
development of products and procedures to treat atrial fibrillation,
has also been named to the Omeris board.
"UC's Academic Health Center is a leader
in forming partnerships with industry and academic institutions to
enhance our research efforts, improve upon our patient care and provide
world-class education," says Dr. Henney. "I am pleased to join this
'force' of academic and business leaders to enhance Ohio's position as
a biotechnology leader."
Omeris also announced the election of
David Scholl, PhD, to chairman of the board. He is president and CEO of
Diagnostic Hybrids in Athens, Ohio, which develops and manufactures
diagnostic cell cultures and virus detection kit systems used in the
clinical diagnosis of infectious and autoimmune diseases. Dr. Scholl
has been an Omeris board member since 2002.
The Omeris Board of Trustees also
includes: John Bantle II, PhD, Ohio University; Timothy Biro, Ohio
Innovation Fund; Mark Collar, Procter & Gamble Pharmaceuticals;
Tony Dennis, PhD, Omeris; Joseph Hahn, MD, the Cleveland Clinic
Foundation; Peter Kleinhenz, CID Equity Partners; John Rice, PhD,
Triathlon Medical Ventures; Richard Rosen, Battelle; Fred Sanfilippo,
MD, PhD, Ohio State University; Bill Sanford, SYMARK; Jim Scozzie, PhD,
BioEnterprise; and Donald Wetherhold, RxPedite.